Direct Line April 2026: Stopping Ozempic and Lifting With Osteopenia

In this April 2026 episode of the Barbell Medicine Podcast's Direct Line, Dr. Jordan Feigenbaum and Dr. Austin Baraki tackle the critical question of what happens when patients stop using GLP-1 medications like semaglutide and tirzepatide. Drawing on multiple clinical trials—including Surmount-4, STEP, and systematic reviews—the hosts reveal that, on average, patients regain about two-thirds of their lost weight within a year of discontinuation. However, they emphasize that this weight regain is not unique to GLP-1s; lifestyle-only interventions also fail to sustain weight loss long-term, with less than 10% of participants maintaining clinically significant weight loss after 10 years. The discussion reframes GLP-1s not as a cure but as a powerful tool that helps patients overcome the body’s natural resistance to weight loss, allowing them to build lasting habits. The conversation then shifts to osteopenia and strength training, where the hosts debunk the myth that heavy lifting is dangerous for bone health. They highlight the landmark Lift More trial, showing that high-intensity resistance training (85%+ 1RM) significantly increased bone mineral density in postmenopausal women with osteopenia, with no fractures and only minor side effects. The key message: bone is adaptable, and strength training is not only safe but essential for reducing fall risk and improving resilience. The episode concludes with sponsor highlights and a call for listeners to submit questions for the next month’s Direct Line.